Press release
Diabetic Macular Edema Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Celltrion, Exonate, Opthea, AsclepiX, Allgenesis, Ascentage, Rezolute, Ocuphire, Oxurion, MingSight, Mylan
"Diabetic Macular Edema Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetic Macular Edema Therapeutics Market.
The report provides a detailed description of the Diabetic Macular Edema drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Diabetic Macular Edema Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Diabetic Macular Edema Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Diabetic Macular Edema therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Macular Edema treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Diabetic Macular Edema drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Diabetic Macular Edema treatment market.
Learn More about the Clinical and Commercial Development Activities in the Diabetic Macular Edema Therapeutics Domain:
https://www.delveinsight.com/report-store/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Diabetic Macular Edema Therapeutics Analysis
Diabetic Macular Edema treatment mainly involves the usage of anti-VEGF Drugs, corticosteroids, and Laser photocoagulation. Nonsteroidal anti-inflammatory drugs (NSAIDs), in the form of eye drops, are sometimes used either before or after cataract surgery to prevent the development of macular edema. Currently, intravitreal anti-VEGF agents are the preferred first-line treatment for Diabetic Macular Edema.
The three most used anti-VEGF drugs are Avastin, Eylea, and Lucentis. These drugs block the activity of VEGF and slow the progress of macular edema. Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, implants, or injections of sustained-release corticosteroids into or around the eye. US FDA-approved sustained-release corticosteroid implants for more serious or longer-lasting conditions are Ozurdex, Retisert, and Iluvien.
There are approx. 60+ key companies developing therapies for Diabetic macular edema. Some of the drugs in the pipeline include Beovu (brolucizumab) (Novartis), Faricimab (Roche), KSI-301 (Kodiak Sciences), ADVM022 (Adverum Biotechnologies),APX3330 (Ocuphire Pharma), THR-149 (Oxurion), UBX1325 (Unity Biotechnology) and several others. Currently, Mylan Pharmaceuticals is leading the therapeutics market with its Diabetic macular edema drug candidates in the most advanced stage of clinical development.
Diabetic Macular Edema Companies in the Therapeutics Market Include:
• Mylan Pharmaceuticals
• Kodiak sciences
• Celltrion
• Exonate
• Opthea
• AsclepiX Therapeutics
• Allgenesis Biotherapeutics
• Ascentage Pharma
• Rezolute
• Ocuphire Pharma
• Oxurion
• MingSight Pharmaceuticals
• Adverum Biotechnologies
And Many Others
Emerging and Marketed Diabetic Macular Edema Therapies Covered in the Report Include:
• MYL-1701P: Mylan Pharmaceuticals
• KSI-301: Kodiak sciences
• CT-P42: Celltrion
And Many More
Get an in-depth Assessment of the Emerging Therapies and Diabetic Macular Edema Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Diabetic Macular Edema Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Diabetic macular edema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Diabetic Macular Edema Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Diabetic Macular Edema Current Treatment Patterns
4. Diabetic Macular Edema - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Diabetic Macular Edema Late-Stage Products (Phase-III)
7. Diabetic Macular Edema Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Diabetic Macular Edema Discontinued Products
13. Diabetic Macular Edema Product Profiles
14. Diabetic Macular Edema Companies
15. Diabetic Macular Edema Drugs
16. Dormant and Discontinued Products
17. Diabetic Macular Edema Unmet Needs
18. Diabetic Macular Edema Future Perspectives
19. Diabetic Macular Edema Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Macular Edema Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Celltrion, Exonate, Opthea, AsclepiX, Allgenesis, Ascentage, Rezolute, Ocuphire, Oxurion, MingSight, Mylan here
News-ID: 3241801 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
